Key Points – Canopy Growth’s fiscal Q1 2027 revenue rose 13% to C$81.2 million, with year-over-year growth across its cannabis and Storz & Bickel businesses.
Adjusted EBITDA loss narrowed 59% to C$3.2 million, and management reiterated its target of achieving positive adjusted EBITDA during fiscal 2027. – Cannabis revenue increased 14%, led by 22% growth in Canadian medical cannabis and 10% growth in both adult-use and international markets
The company expects U.K. flower shipments to begin soon, with revenue contributions anticipated in the second half of fiscal 2027. – Management is prioritizing cultivation improvements, supply-chain efficiencies and MTL Cannabis synergies to expand margins. Adjusted consolidated gross margin improved to 31%, while Canopy is targeting mid-30% margins in the near term and is executing against C$8 million of annualized MTL synergies. – The 2026 Cannabis Wildcard: How Tax Reform Could Reset Stock Valuations Canopy Growth (NASDAQ:CGC) reported first-quarter fiscal 2027 net revenue of C$81.2 million, up 13% from the prior-year period, as the company recorded year-over-year growth across its cannabis and Storz & Bickel businesses. Chief Executive Officer Luc Mongeau said the quarter marked the first time since he joined the company in January 2025 that Canopy reported year-over-year growth in each of its business lines.
He attributed the progress to efforts undertaken during fiscal 2026 to sharpen operations, reduce costs and integrate MTL Cannabis, which Canopy acquired in March. – Constellation Brands: A Fallen Star or a Hidden Value Play? “Fiscal 2027 is about growth and moving our focus to cultivation to improve yields and accelerate growth, especially in Europe,” Mongeau said. He added that the company is also increasing manufacturing efforts to improve margins and advance toward positive adjusted EBITDA. Revenue Growth Across Cannabis Channels Canopy’s cannabis segment grew 14% year over year during the quarter.